权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Molecular Engineering and Antibody Production

分子工程和抗体生产

基本信息

批准号：
7728851
负责人：
Robert M Sharkey
金额：
$ 6.83万
依托单位：
CTR FOR MOLECULAR MEDICINE/IMMUNOLOGY
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
起止时间：
2008-08-01 至 2009-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7728851
关键词：
18 year old Antibodies Antibody Formation Area Ascites Binding Bispecific Antibodies Boxing Budgets CD20 Antigens CD22 gene Carbon Dioxide Cells Certification Charge Chromatography Class Clinical Clinical Research Condition Core Facility Cultured Cells DOTA-biotin Deferoxamine Development Developmental Therapeutics Program Documentation Engineering Ensure Environment Epratuzumab Equipment Fermentation Freeze Drying Funding Glass Glycine Guanosine Monophosphate High Pressure Liquid Chromatography Histamine Housing Human Resources Hybridomas Immunoelectrophoresis Immunoglobulin G Incubators Institution Iron binding capacity measurement Keyhole Limpet Hemocyanin Laboratories Laboratory Research Learning MS4A1 gene Mammalian Cell Methotrexate Molecular Monoclonal Antibodies Multiple Myeloma Mus New Brunswick Non-Hodgkin&apos s Lymphoma Participant Pentetic Acid Peptides Peroxidase Peroxidases Pharmacologic Substance Phase I Clinical Trials Pichia Preparation Procedures Process Product Labeling Production Property Pump Purpose Pyrogens Reagent Recombinants Research Research Personnel Rest Roller Bottle Standards of Weights and Measures System Testing Time Training Ultrafiltration Work Writing air filter antibody conjugate antibody engineering base cell growth cost experience foot pressure programs research study size tissue culture

项目摘要

The primary objective of this core is to provide antibody reagents for participants in this program project. CMMI's Antibody Production Core has operated for the past 20 years producing antibodies for research and clinical use. This core has the ability to produce and purify gram quantities of antibody from hybridoma cells growing in tissue culture. It operates in a Class 100,000 work area under GLP conditions with written procedures and full documentation of all purified products. This lab also prepares conjugates of antibodies, such as DTP A, DOTA, biotin, peroxidase, KLH, and others that are used for a variety of purposes. Over the past year, CMMI has collaborated with IBC Pharmaceuticals, Inc. to develop and produce recombinant bispecific antibodies (bsMAb). The laboratory currently operates a small-scale fermenter and has been, involved in the production of antibodies in E. coll and Pichia. More recently, these same bsMAb constructs have been expressed in mammalian cells so that they can be manufactured more easily in existing GMP cell culture facilities. For this Program Project, this laboratory will be involved in the production of antibodies to non-Hodgkin's lymphoma and multiple myeloma, including humanized antibodies to CD20, CD22, and CD74. Chemically conjugated bispecific antibodies, as well as DOTA, DTPA, NOT A, and deferoxamine conjugates will be prepared for research studies. Two newly recombinant bispecific antibodies will be prepared using a humanized anti-CD20 and a humanized anti-HSG (histamine-succinyl-glycine) antibody. One of these clones will be developed and produced for clinical use.

该核心的主要目标是为该项目的参与者提供抗体试剂。